SNYSanofiRunning, no new patients
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Plasma Cell Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 475 (final count)
- Started
- Dec 7, 2017
- Main results expected
- Apr 5, 2027
- Fully finished
- Jun 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS)
Measured over: Up to approximately 100 months after the First Participant In (FPI)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03319667 · record last updated 2026-05-04 · checked 2026-11-09 15:47 UTC